Compare Boston Scientific Corporation (BSX) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Oklo Inc — how do they compare? Boston Scientific Corporation trades at $43.55 (market cap $66.37B), while Oklo Inc trades at $45.8 (market cap $8.05B). The key difference: Boston Scientific Corporation is far larger — about 8.2× Oklo Inc's market cap. Which is the better fit depends on your goals.
| BSX | OKLO | |
|---|---|---|
Market Cap | $66.37B | $8.05B |
Sector | Health | Technology |
52-Week High | $108.14 | $174.14 |
52-Week Low | $42.63 | $45.58 |
Enterprise Value | $75.94B | $5.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
OKLO stock trades at $45.81, down 6.22% in the last session, reflecting ongoing volatility. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but faces fundamental challenges with negative ROE (-8.87%) and net income (-$105.66M). Recent DOE approval for the Groves Isotope Test Reactor represents a key regulatory milestone, though cash flow remains heavily dependent on financing activities.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. While analyst targets suggest 98% upside, the company must navigate regulatory hurdles and achieve profitability amid negative earnings trends. The stock's bearish technical signals and high valuation multiples require careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
